# Viking Therapeutics, Inc. (VKTX): Analyst Ratings Highlight a Potential 234% Upside for Investors

- Link: https://www.directorstalkinterviews.com/viking-therapeutics-inc-vktx-analyst-ratings-highlight-a-potential-234-upside-for-investors/4121202662
- Published: 2025-06-17T10:39:14+01:00
- Author: Madison Wilson

Viking Therapeutics, Inc. (NASDAQ: VKTX) is capturing investor attention with its
strong potential for substantial gains. Known for its innovative approach in the
biotechnology sector, Viking Therapeutics is carving its niche in the healthcare
industry with a promising pipeline of drug candidates targeting metabolic and endocrine
disorders. Despite a current price of $26.96, the stock is poised for significant
growth, with analyst ratings suggesting a potential upside of 234.80%, placing the
average target price at an impressive $90.26.

As a clinical-stage biopharmaceutical company, Viking Therapeutics is focused on
the development of novel therapies with its lead candidate, VK2809, making waves
in Phase IIb clinical trials. This orally available drug targets non-alcoholic steatohepatitis(
NASH) and non-alcoholic fatty liver disease (NAFLD), both of which are areas of 
high unmet medical need. The company’s robust pipeline also includes VK5211 for 
hip fracture recovery, VK0612 for type 2 diabetes, VK2735 as a dual agonist for 
metabolic diseases, and VK0214 for X-linked adrenoleukodystrophy, showcasing a diversified
therapeutic focus.

The company’s financial metrics reflect its developmental stage, with a market capitalization
of $3.03 billion and a forward P/E ratio of -10.83, indicative of anticipated losses
as is common in the biotech industry. While the EPS currently stands at -1.16, and
the return on equity is -14.40%, these figures are not unusual for companies at 
this stage, where significant R&D investments are essential.

Viking’s performance metrics, such as free cash flow of -$98.38 million, suggest
a company heavily investing in its future, with no revenue growth or net income 
reported as yet. The absence of dividend yield and a payout ratio of 0.00% further
underscore the reinvestment strategy aimed at advancing its drug candidates through
clinical trials.

Analyst sentiment remains overwhelmingly positive, with 17 buy ratings and only 
2 hold ratings, and no sell ratings, underscoring confidence in Viking’s strategic
direction and potential for growth. The target price range of $30.00 to $125.00 
reflects both cautious optimism and high expectations from analysts.

On the technical front, Viking’s stock is showing relative stability, with a 50-
day moving average of $26.39, slightly below the current price, and a 200-day moving
average of $41.82, reflecting past volatility. The Relative Strength Index (RSI)
of 54.06 suggests the stock is neither overbought nor oversold, providing a balanced
view of its current trading position.

As Viking Therapeutics continues to advance its clinical trials and expand its therapeutic
portfolio, the potential for significant returns is evident. For investors seeking
exposure to the high-risk, high-reward biotech sector, Viking Therapeutics offers
a compelling proposition with its cutting-edge research and promising drug candidates.
With a strategic focus on addressing critical health issues and a solid backing 
from analysts, Viking Therapeutics is a stock worth watching closely.

Share on:
